publication date: Oct. 4, 2019
NCI Trials
NCI Trials for October
The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month.
For further information, contact the principal investigator listed.
Phase I – ABTC-1804
Determining the Dose of Regadenoson Most Likely to Transiently Alter the Integrity of the Blood-Brain Barrier in Patients with High Grade Gliomas
Adult Brain Tumor Consortium
Grossman, Stuart Alan
(410) 955-8837
Phase II – ACNS1723
A Phase 2 Study of Dabrafenib (NSC# 763760) with Trametinib (NSC# 763093) After Local Irradiation in Newly-Diagnosed BRAF V600-Mutant High-Grade Glioma (HGG) (IND# 145355)
Children’s Oncology Group
Lulla, Rishi Ramesh
(401) 444-5171
Phase III – A221803
Mepitel Film for the Reduction of Radiation Dermatitis in Breast Cancer Patients Undergoing Post-Mastectomy Radiation Therapy: A Randomized Phase III Clinical Trial
Alliance for Clinical Trials in Oncology
Corbin, Kimberly S.
(507) 284-2669
Phase Other – WF-1805CD
Implementation and Effectiveness Trial of HN-STAR
Wake Forest NCORP Research Base
Weaver, Kathryn E.
(336) 713-5062
